The effects of orlistat on metabolic parameters and other cardiovascular risk factors.
Orlistat is an antiobesity drug with a well documented efficacy in weight reduction and weight maintenance. Weight reduction with orlistat has been associated with a favourable effect on obesity-related cardiovascular risk factors. Orlistat treatment is associated with a reduction in serum insulin levels. Moreover, orlistat reduces the incidence of type 2 diabetes in patients with impaired glucose tolerance and lowers the required dose of metformin, sulfonylureas and insulin in patients with type 2 diabetes. Furthermore, orlistat can reduce total and low density lipoprotein (LDL) cholesterol levels and improve postprandial triglyceridemia, as well as the low density lipoprotein cholesterol/high density lipoprotein cholesterol ratio (LDL/HDL ratio). Moreover, orlistat appears to have a favourable effect on some inflammatory markers, such as TNF-alpha and interleukin-6 and has a time-depended effect on some haemostatic factors.
Kiortsis
D N
DN
Laboratory of Physiology and Department of Internal Medicine, University of Ioannina, 45110, Ioannina, Greece.
Filippatos
T D
TD
Elisaf
M S
MS
D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D001053:Apolipoproteins / Q000187:drug effects / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000517:prevention & control; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D008074:Lipoproteins / Q000378:metabolism; D000077403:Orlistat; D012307:Risk Factors; D014280:Triglycerides / Q000378:metabolism; D015431:Weight Loss / Q000187:drug effects*
D019440:Anti-Obesity Agents; D001053:Apolipoproteins; D005230:Fatty Acids, Nonesterified; D007783:Lactones; D008074:Lipoproteins; D014280:Triglycerides; D000077403:Orlistat